<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085251</url>
  </required_header>
  <id_info>
    <org_study_id>IDT-1653-LI</org_study_id>
    <nct_id>NCT03085251</nct_id>
  </id_info>
  <brief_title>Clinical System Accuracy Evaluation With OneTouch® Verio Flex Blood Glucose Monitoring System (BGMS)</brief_title>
  <official_title>Clinical System Accuracy Evaluation With OneTouch® Verio Flex Blood Glucose Monitoring System (BGMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LifeScan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is the evaluation of system accuracy based on EN ISO 15197:2015&#xD;
      (ISO 15197:2013), clause 6.3 in which accuracy requirements and applicable test procedures&#xD;
      for blood glucose monitoring systems intended for self-monitoring of blood glucose by&#xD;
      patients are stipulated. ISO 15197:20132 was harmonized with the regulations of the European&#xD;
      Union as EN ISO 15197:2015. This harmonization had no impact on the requirements and&#xD;
      procedu¬res in ISO 15197:2013; changes were made to the foreword and an informative annex. In&#xD;
      this study, system accuracy evaluation will be performed for OneTouch® Verio Flex (LifeScan&#xD;
      Europe) on behalf of LifeScan Scotland Limited (customer) with three different reagent system&#xD;
      lots.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Actual">June 1, 2017</completion_date>
  <primary_completion_date type="Actual">April 3, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>System accuracy criteria</measure>
    <time_frame>For each subject, the experimental phase has an expected duration of up to 6 hours</time_frame>
    <description>Based on EN ISO 15197:2015 (ISO 15197:2013) (E), the BGMS shall meet both of the following criteria:&#xD;
Criterion A: 95 % of the measured glucose values shall fall within either ± 15 mg/dl (0.83 mmol/l) of the average comparison measurement result at glucose concentrations &lt; 100 mg/dl (5.55 mmol/l) or within ± 15 % at glucose concentrations ≥ 100 mg/dl (5.55 mmol/l).&#xD;
Each lot shall pass acceptability criterion A. Criterion B: 99 % of individual glucose measured values shall fall within zones A and B of the Consensus Error Grid (CEG) for type 1 diabetes.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Blood glucose measurement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood glucose monitoring systems for self-testing (BGMS)</intervention_name>
    <description>Measurement procedure&#xD;
Subjects will be asked to wash and dry their hands before the measurements.&#xD;
The measurement procedure for each reagent system lot of a BGMS will be as follows:&#xD;
Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.&#xD;
Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.&#xD;
Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.&#xD;
The sample will be applied to the reagent system units following specifications in the manufacturer's labelling.</description>
    <arm_group_label>Blood glucose measurement</arm_group_label>
    <other_name>OneTouch® Verio Flex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, with type 1 diabetes, type 2 diabetes (or subjects without diabetes)&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Minimum age of 18 years&#xD;
&#xD;
          -  Subjects are legally competent and capable to understand character, meaning and&#xD;
             consequences of the study.&#xD;
&#xD;
          -  If blood glucose values &lt; 80 mg/dl or &gt; 300 mg/dl shall be measured after short term&#xD;
             alteration in insulin therapy:&#xD;
&#xD;
          -  Male or female with type 1 diabetes and intensified insulin therapy or insulin pump&#xD;
             therapy.&#xD;
&#xD;
          -  Signature of subjects to document consent with these procedures on informed consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Severe acute disease (at the study physician's discretion)&#xD;
&#xD;
          -  Severe chronic disease with potential risk during the test procedures (at the study&#xD;
             physician's discretion)&#xD;
&#xD;
          -  Current constitution that compromises the subject's capability to participate in the&#xD;
             study (at the study physician's discretion)&#xD;
&#xD;
          -  Being unable to give informed consent&#xD;
&#xD;
          -  &lt; 18 years&#xD;
&#xD;
          -  Legally incompetent&#xD;
&#xD;
          -  Being committed to an institution (e.g. psychiatric clinic)&#xD;
&#xD;
          -  Language barriers potentially compromising an adequate compliance with study&#xD;
             procedures&#xD;
&#xD;
          -  Dependent on investigator or sponsor&#xD;
&#xD;
          -  If blood glucose values &lt; 80 mg/dl shall be measured after short term alteration in&#xD;
             insulin therapy (concentration category 2), subjects with type 1 diabetes, suffering&#xD;
             from:&#xD;
&#xD;
          -  Coronary heart disease&#xD;
&#xD;
          -  Condition after myocardial infarction&#xD;
&#xD;
          -  Condition after cerebral events&#xD;
&#xD;
          -  Peripheral arterial occlusive disease&#xD;
&#xD;
          -  Hypoglycemia unawareness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

